Omega Funds Co-Investors 2026

Who Omega Funds invests alongside: Abingworth, Atlas Venture, Biotechnology Value Fund — mapped across 15 portfolio companies in 2 sectors and 11 cities.

Omega Funds accounts for 48 tracked companies with verified cap-table data, 48 of which disclose round sizes totalling $11B. The median disclosed raise is $165M, and the largest is Morphic Therapeutic at $3.2B, ahead of Sana Biotechnology ($700M) and Alumis ($529M).

The names that recur most often on these co-invested cap tables are Omega Funds (48 companies), Cormorant Asset Management (7 companies), Jeito Capital (6 companies), Novartis Venture Fund (6 companies), Atlas Venture (6 companies), Surveyor Capital (6 companies). By latest disclosed round, the market skews Series A (18), Series B (15), Series C (6), Growth (3).

Best funded Omega Funds companies

  1. Morphic Therapeutic — $3.2B (latest: Series B)
  2. Sana Biotechnology — $700M (latest: IPO)
  3. Alumis — $529M (latest: Series C)
  4. Immunic Therapeutics — $400M (latest: Growth)
  5. Beta Bionics — $333M (latest: Series E)
  6. Catalym — $319M (latest: Series D)
  7. Endeavor BioMedicines — $292M (latest: Series A)
  8. Nuvation Bio — $275M (latest: Series A)
  9. ARTBIO — $245M (latest: Series B)
  10. Aviceda Therapeutics — $210M (latest: Series C)
  11. Attralus — $201M (latest: Series B)
  12. BridgeBio Oncology Therapeutics — $200M (latest: Growth)
  13. Upstream Bio — $200M (latest: Series A)
  14. Windward Bio — $200M (latest: Series A)
  15. Alveus Therapeutics — $197M (latest: Series A)

Omega Funds headquarters — related firms and companies (56)

Omega Funds headquarters profile · All research reports